Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study

What Was Tested

Researchers studied Liraglutide in this randomized controlled trial publication.

Patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) exhibit considerable residual risk for cardiovascular disease (CVD).

Here the researchers investigated the effects of liraglutide intervention on ectopic fat depots, hepatic lipogenesis and fat oxidation, postprandial lipid metabolism and glycaemia in humans with type 2 diabetes.

Who Took Part

The study group was 22 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Liraglutide study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.

Because liraglutide is known to promote weight loss, the study included dietary counselling to achieve similar weight loss in the liraglutide and placebo groups.

Cardiometabolic responses to a high-fat mixed meal were measured before and at the end of the liraglutide intervention.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Lipid Metabolism, Liraglutide, Liver and Postprandial Period.

The authors tagged it with the keywords GLP-1-agonist, apolipoprotein C3, atherogenic dyslipidaemia, liver fat, postprandial lipids and remnant lipoproteins.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Liraglutide in 22 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Liraglutide compound page.